How long does it take to see the effects of Platinib?

Pralsetinib (Pralsetinib) is an oral drug that is a targeted treatment for tumors. It is a RET (rearranged during transfection) protein kinase inhibitor used to treat a type of tumor called RET gene rearrangement-positive tumors. Platinib has shown good efficacy in some tumors with RET gene rearrangements. These tumors include thyroid cancer, non-small cell lung cancer, and other rare cancer types. By inhibiting the activity of RET kinase, Platinib blocks the growth and spread of cancer cells, thereby reducing tumor size and number.

Based on study data, plasma concentrations of platinib reach a steady state after 3 to 5 days. After repeated oral administration once daily, the average accumulation rate is approximately 2 times. Platinib has demonstrated significant anti-tumor activity in clinical trials. In a study of patients with advanced or metastatic thyroid cancer, more than 60% of patients treated with platinib experienced tumor shrinkage. In addition, platinib has also shown considerable efficacy in other types of studies, such as non-small cell lung cancer. However, the therapeutic efficacy of platinib will vary depending on individual differences and disease status. Some patients may develop resistance to platinib or experience adverse drug reactions.

To sum up, the onset time of platinib is a complex issue and is affected by many factors. Generally speaking, most patients are likely to see some benefit within a month of taking platinib. However, that doesn't mean everyone will see effects within this time frame. Some patients may take longer to see significant effects, and some may even be insensitive or resistant to platinib due to various reasons and cannot obtain the expected therapeutic effects.